[HTML] sciencedirect.com

[HTML][HTML] In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

M Behr, J Zhou, B Xu, H Zhang - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has
been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly …
被引用次数：144 相关文章
[PDF] researchgate.net

[PDF][PDF] In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

M Behr, J Zhou, B Xu, H Zhang - researchgate.net
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has
been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly …
[HTML] nih.gov

[HTML][HTML] In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

M Behr, J Zhou, B Xu, H Zhang - Acta Pharmaceutica Sinica. B, 2021 - ncbi.nlm.nih.gov
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has
been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly …

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges.

M Behr, J Zhou, B Xu, H Zhang - Acta Pharmaceutica Sinica. B, 2021 - europepmc.org
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has
been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly …

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

M Behr, J Zhou, B Xu, H Zhang - Acta pharmaceutica …, 2021 - pubmed.ncbi.nlm.nih.gov
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has
been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly …